Board of Directors


gary-kennedyGary Kennedy is Remedy’s Founder, Chief Executive Officer and chief visionary, defining the company’s strategic focus on translational research informatics products. Before launching Remedy, he served as President and CEO of TenFold. Mr. Kennedy served as President, CEO and Chairman of PRC, Inc. Prior to joining PRC, Mr. Kennedy held a variety of management and executive positions at Oracle Corporation, including National Sales Manager, Senior Vice-President of Oracle Corporation and President of Oracle USA. He was one of the first twenty employees of Oracle. Prior to joining Oracle he served as a Marketing Manager for Intel Corporation.

In addition to serving as Remedy’s CEO for the past eight years, Mr. Kennedy is the founder and managing partner of Double Eagle Ventures, a private venture fund targeting seed stage investments in the United States and Brazil. Gary holds a B.A. in finance from the University of Utah and a Masters in Business Administration from Northwestern University’s Kellogg Graduate School of Management. He currently serves on the Board of Directors of several private companies and was named Utah Entrepreneur of the Year in 1999 by Ernst and Young.



Duff Thompson is managing general partner of EsNet and a managing member of E-Net Teo LLC. He has been active in the technology industry since the mid-1980′s serving as Executive Vice President and General Counsel for WordPerfect Corporation from 1986-1994, and Senior Vice President of Novell, Inc. from 1994-1996. Prior to working with WordPerfect Corporation, Mr. Thompson was a partner in the firm of Callister, McCullough and Nebeker, working there from 1983-1986.

Mr. Thompson has served as a past chairman of the Business Software Alliance, and currently serves on the Board of Directors of Santa Cruz Operation. Mr. Thompson holds a bachelor degree in Economics from Brigham Young University, together with both a Masters in Business Administration and J.D. degree, also from Brigham Young University.


Adam-SlovikAdam Slovik is a software executive with years of management, consultant and investor experience. From 2006 to 2011, Adam Slovik held various positions at Remedy, including EVP of Sales and Marketing. Prior to joining Remedy, Mr. Slovik was a consultant to startup CEOs, advising companies on strategy and management. In 1993, Mr. Slovik co-founded TenFold Corporation, a provider of applications development and infrastructure technologies, where he held numerous senior management roles. Mr. Slovik conceived and created TenFold’s patented Universal Application™, platform that enables business analysts to rapidly build and deploy applications.

Prior to TenFold, Mr. Slovik was a founding member of Oracle Corporation’s Applications Division and served in various technical, architectural and product management roles. A frequent lecturer on entrepreneurship, management, strategies and tactics for growing companies, Mr. Slovik is also a guest speaker to entrepreneurship classes at the Haas School of Business at UC Berkeley. Mr. Slovik earned a Bachelor of Science from the California Institute of Technology.


Joe-Volpe-MerckJoe Volpe is a Managing Director for Merck Global Health Innovation Group overseeing its evergreen Health Technology portion of the fund. His technology, business development and technical engineering background are coupled with an in-depth understanding of emerging technologies in the health care industry. These unique aptitudes provide Mr. Volpe with the foundation and knowledge to enable sound Health IT investments and acquisition.

Mr. Volpe adds strategic value to Merck’s core business model by taking a stakeholder-neutral view of the healthcare IT landscape. He focuses on Venturing and M&A efforts with special focus on health data access and liberation, health informatics and analytics and value-added HIT productivity enablers. To date Mr. Volpe has lead investments and/or acquisitions in companies such as Liaison Technologies, Preventice, MiHealth, Physicians Interactive, Medivo, Remedy Informatics and ClearDATA.

Prior to joining Merck, Mr. Volpe’s 28-year career included a post serving within Johnson & Johnson’s Market Place Innovation team. He was responsible for technology innovations across Consumer, Medical Device and Diagnostics and Pharmaceutical sectors. Additionally, he has coordinated business development opportunities in the IT health care arena with concentration on applications in the evidence-based Medicine/Outcomes/e-marketing and sales platforms.

Mr. Volpe spent more than a decade with J&J Corporate Innovations division and Strategic Development group dealing directly with consumer, device and pharmaceutical companies that were developing and deploying innovative health care strategies and investments, across areas such as Physician systems, managed markets platforms, e-prescribing organizations, consumer and professional sales, marketing, customer marketing and call center arenas.

He began his career as a Systems Engineer with Electronic Data Systems (EDS) working with health care insurance systems, military systems and robotics. He earned his Bachelor of Information Systems from the University of South Florida with a minor in Engineering Technology, and later graduated from a two-year EDS Engineering program.

A well-respected industry professional, he has presented at venture oriented speaker panels, and conferences including the Microsoft CIO Summit, HIMSS and numerous venture forum conferences.

Mr. Volpe presently sits on numerous boards including Physicians Interactive, Liaison, Preventice, Medivo, HealthSense, ClearDATA and Mihealth.


Resnick_smJon Resnick is vice president and general manager, Real World Evidence (RWE) Solutions for IMS Health, responsible for global RWE and health economics and outcomes research initiatives. RWE focuses on the development and application of information, technology and analytics to meet the evidence needs of payers, regulators and other scientific and commercial stakeholders.

Mr. Resnick joined IMS Health’s management consulting business in 2002, where he advised pharmaceutical and biotechnology clients on corporate, organizational and product strategy. Since 2006, he has held several leadership positions within IMS Health, including regional leader for the IMS Consulting Group in Europe and practice leader for the company’s Pricing and Market Access business in EMEA. Prior to joining IMS Health, Mr. Resnick served as professional health and social security staff for the U.S. Senate Committee on Finance in Washington D.C. He was responsible for advising committee members and other senators on policy issues, developing legislation and supporting the legislative process on issues, including Medicare, Medicaid and health reform.

Mr. Resnick holds a bachelor’s degree in Political Science from Union College and a Masters of Business Administration from the Kellogg School of Management, Northwestern University.


Tom HawkinsTom Hawkins has more than 24 years of venture capital, entrepreneurial and operational experience. In 2012, Tom founded Forté Ventures, a multi-stage venture capital firm that collaborates and co-invests with corporate strategic partners in Information Technology and Industrial Technology companies throughout North America. Investments range from $100,000 up to $3 million and typically include participation from leading corporate strategic partners and co-investors. The firm has primary offices in Atlanta and Silicon Valley.

Prior to Forté Ventures, Mr. Hawkins co-founded the Venture Capital line of business at Arcapita Bank in 2005 and Arcapita Ventures raised a $200 million growth stage venture capital fund in 2006. Tom managed investment activity in the IT, communications, energy and industrial technology sectors.

Prior to Arcapita, he was an Investment Partner with the Corporate Fund of Siemens Venture Capital, the $850 million venture capital arm of Siemens AG (NYSE: SI), where he managed investment activity in IT, communications and industrial automation & control technology.

Prior to Siemens, Mr. Hawkins was a General Partner with Cordova Ventures, a $250 million venture capital firm in Atlanta, where he focused on enterprise and infrastructure software, communications and industrial technology. Prior to Cordova, he managed Strategic Business Development at Radiant Systems, which was acquired by NCR (NYSE: NCR) in 2011.

He currently serves as an active member of the Executive Committee of the Board of Directors of Junior Achievement of Georgia. He also serves on the Board of Directors of Remedy Informatics and Arisdyne Systems. He previously served on the Board of Directors of Navini Networks (acquired by Cisco), SmartSynch (acquired by Itron), Digital Envoy (acquired by Landmark Communications), Intelleflex, Zeuss, Qcept Technologies, ManageSoft and Quellan.

Mr. Hawkins earned his B.A. degree from Duke University in 1992 and his Masters of Business Administration from the Kellogg School of Management at Northwestern University in 1999.


Sachin_JainSachin H. Jain, MD, MBA is Chief Medical Information and Innovation Officer (CMIIO) at Merck and Lecturer in Health Care Policy at Harvard Medical School. He also serves as an attending hospitalist physician at the Boston VA–Boston Medical Center.

In his capacity as Merck’s CMIO, Dr. Jain is working to establish and manage global alliances to use health data to improve medication safety, efficacy, use, and adherence. He is also leading several efforts around new ventures and business development.

Previously, Dr. Jain was Senior Advisor to the Administrator of the Centers for Medicare and Medicaid Services (CMS), where he helped lead the launch of the Center for Medicare and Medicaid Innovation, briefly serving as its Acting Deputy Director for Policy and Programs. While at CMS he also advocated for speedier translation of health care delivery research into practice and an expanded use of clinical registries.

Dr. Jain also served as Special Assistant to the National Coordinator for Health Information Technology at the Office of the National Coordinator for Health Information Technology (ONC). There, he worked with David Blumenthal to implement the HITECH Provisions of the Recovery Act that provide incentives for physicians and hospitals to become meaningful users of health information technology.

In addition, Dr. Jain has worked for WellPoint, McKinsey & Co., and the Institute for Healthcare Improvement; served as an expert consultant to the World Health Organization; and maintained a faculty appointment at Harvard Business School’s Institute for Strategy and Competitiveness, where he worked with strategy professor Michael Porter on a new case literature on healthcare delivery innovation.

An honorary Senior Institute Associate at Harvard Business School, Dr. Jain is a founder of several non-profit healthcare ventures and author of more than 50 publications on healthcare delivery innovation and healthcare reform in journals that include the New England Journal of Medicine, JAMA, and HealthAffairs. He also serves on the editorial boards of the American Journal of Managed Care, Harvard Medicine, and Wing of Zock.

Dr. Jain received his undergraduate degree in government, magna cum laude, from Harvard College; his medical degree from Harvard Medical School; and his master’s degree in business administration from the Harvard Business School. He was a recipient of the Paul and Daisy Soros Fellowship and the Dean’s Award at Harvard Business School. Dr. Jain completed his residency in internal medicine at Brigham and Women’s Hospital, where he was honored with the Resident Mentor Award.